CALGARY, ALBERTA--(Marketwire - February 20, 2008) - Stem Cell Therapeutics Corp. (“SCT”) (TSX VENTURE: SSS) is pleased to announce favorable results from the investigator led BETAS (Beta-hCG + Erythropoietin in Acute Stroke), Phase IIa, open label, safety trial conducted at the University of California, Irvine and Hoag Presbyterian Memorial Hospital, Newport Beach, CA. This trial is the first to test the safety of NTx™-265 in patients suffering acute ischemic stroke and to conduct a preliminary assessment of functional recovery in this patient population.
